"The therapeutic candidate comprises of T-cells genetically engineered to express chimeric antigen receptor (CAR) targeting cells expressing kallikrein 2 (KLK2)."
we talked about kallikrein just yesterday...I think she came from LA?
here we go: JNJ-9414 phase 1 - Advanced Prostate...
here we go: JNJ-9414 phase 1
Written by
Maxone73
To view profiles and participate in discussions please or .
2 Replies
•
Where are we going?
Here we go with another study that refers to this kallikrein from LA!
Not what you're looking for?
You may also like...
Here we go again
it is a type of radiation treatment to kill cancer cells, but what else does it kill .. I say no,...
AMG 212 Phase 1 study shows potential.
PSMA-Targeting Bispecific T cell Engager Immunotherapy for Metastatic Castration-Resistant Prostate...
Promising phase 1 trial…
specific biomarkers on cancer cells, wherever they might be, and then enter the tumour cell....
Phase 1-2 study for niclosamide-based drug:
…thought they made cars… 😜
“Hyundai’s formulation claims to have a high enough drug concentration...
Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2)
Phase 1 trial participation Nurix NX-1607
PSMAddition Phase 1/2 Results?
current state of Immuno therapy , how we got here and where we are going - Peter Attia
Started Phase 1 trial - RO7656594 yesterday
